Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Debt (2023 - 2024)

Tonix Pharmaceuticals Holding has reported Total Debt over the past 2 years, most recently at $7.5 million for Q4 2024.

  • Quarterly results put Total Debt at $7.5 million for Q4 2024, down 15.98% from a year ago — trailing twelve months through Dec 2024 was $7.5 million (down 15.98% YoY), and the annual figure for FY2024 was $7.5 million, down 15.98%.
  • Total Debt for Q4 2024 was $7.5 million at Tonix Pharmaceuticals Holding, down from $8.0 million in the prior quarter.
  • Over the last five years, Total Debt for TNXP hit a ceiling of $9.0 million in Q1 2024 and a floor of $7.5 million in Q4 2024.